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... 19 INTRODUCTION
Essential thrombocythaemia (ET), characterized by the excessive proliferation of megakaryocytes in the bone-marrow and the overproduction of circulating platelets in the peripherial blood, which was was first recognized as a distinct clinical syndrome by Emil Epstein and Alfred Godelin in 1934, and in 1951 was listed as one of the classical myeloproliferative neoplasms (MPNs) in the classification by William Dameshek 1-3 .
As ET is characterized by proliferation of the megakaryocytic lineage without significant expansion of the granulocytic and erythroid lineages, the bone-marrow biopsy result frequently reveals a hypercellularity picture with an increased number of enlarged hyperlobated, mature megakaryocytes, without notably increased marrow fibrosis 4 . The peripheral blood smear in many cases demonstrates enhanced numbers of platelets and megakaryocyte fragments 4, 5 . In the initial phase of the disease, many patients are symptomless and the diagnosis is commonly established only fortuitously via a routine blood count. An elevated peripheral platelet count is indicative of the diagnosis of ET if the sustained value is ≥ 450 giga/L and other evidence of reactive thrombocytosis, such as infection, inflammation and other chronic myeloid neoplasms or lymphoproliferative disorders, is excluded 5 . There are cases in which the presence of thrombohaemorrhagic events draw attention to ET as the underlying disease.
It has been reported that the most important complications that can exert major effects on the morbidity and mortality of ET patients are thrombohaemorrhagic events, the risk of which approximately ranges between 11-25% [6] [7] [8] . The risk of microvascular (e.g. headaches, dizziness, visual disturbances, distal paraesthesia, acrocyanosis, and erythromelalgia) and major thrombotic complications (e.g. arterial events: myocardial infarction (MI), ischaemic stroke or a transient ischaemic attack (TIA); venous events: deep venous thrombosis) is higher than the risk of haemorrhagic complications 6, 9 .
The ET-related haemostatic abnormalities and the pathogenesis of the major thrombotic complications or microvascular disturbances seen in ET still pose many questions, and in recent years this topic has been actively investigated 6, 10 . It is currently suggested that not merely the elevated platelet count in the periphery itself, but this together with the consequent qualitative abnormalities of the platelets and other possible additional thrombotic risk factors (e.g. cardiovascular risk factors, leukocytosis and the JAK2 V617F, MPL and CALR mutations may influence the thrombotic complications seen in ET 6, [11] [12] [13] [14] [15] [16] [17] [18] .
The current haematological management strategy in ET is based on thrombosis riskoriented recommendations: patients classified as at low risk (age <60 years, without prior thrombotic event) receive anti-platelet therapy (e.g.: aspirin) if necessary, while high-risk patients (age >60 years and/or with a prior thrombotic event) receive cytoreductive drugs (e.g.: hydroxyurea) alone or in combination with anti-platelet therapy 19, 20 14 . The IPSET score includes a consideration of the predictive potential of the JAK2 V617F mutation and the cardiovascular risk factors (i.e.: high blood pressure, diabetes and active tobacco use). Furthermore, instead of merely the classical high-and low-risk group stratification, it introduces a three-subgroup (IPSET low-risk, IPSET intermediate-risk and IPSET high-risk) stratification model 14 .
Although this score system appears more promising than the conventional two-categorical risk assessment, and may promote a better prediction of major thrombotic complications in ET, it requires confirmation through investigations at more clinical centres.
AIMS
The aim of the current Ph.D work was to create a retrospective study cohort of patients diagnosed with ET at the 2nd Department of Internal Medicine, University of Szeged, between 1999 and 2014, and to evaluate and analyse the following aspects:
I. the occurrence of thrombotic events previously and in the follow-up period;
II. the role of the leukocyte count at the haematological diagnosis as a suggested, but still controversial additional risk factor in the subsequent thrombotic complications;
III. the presence of JAK2 V617F, MPL mutations (W515L, W515K, W515R, W515A, In general, the haematological management strategy was based on risk-oriented recommendations: low-risk patients received anti-platelet therapy (e.g. aspirin) if necessary, while high-risk patients were given cytoreductive drugs (e.g. hydroxyurea) alone or in combination with anti-platelet therapy 7, 19, 20 .
STATISTICAL ANALYSES
Clinical and data for genetic analyses were compiled with Microsoft Office Excel, and subjected to statistical analysis with Statsoft Statistica v 9.1 (Statsoft) and SPSS 20 software (IBM).
Evaluation of the contribution of the leukocyte count
To analyse the possible contribution of the leukocyte count (measured at the time of ET haematological diagnosis) in the prediction of subsequent thrombotic complications, a current patient population-related cut-off value based on bivariate binary logistic regression was first calculated. Optimum regression was used to find the cut-off value of the leukocyte count which had the most balanced predictive value. Mann-Whitney and multivariate binary logistic regression tests were performed in the cases of the presence or absence of thrombotic complications with the following variables: (a) the calculated leukocyte count cut-off related to the current population, and (b) leukocytosis with a median leukocyte count of at least 11.1 giga/L. For a detailed prudent analysis, the presence of prior thrombotic events, an age over 60, the JAK2 V617F mutation, the presence of at least one cardiovascular risk factor and the applied therapy (hydroxyurea or aspirin) as suggested important variables were incorporated in the multivariate binary logistic regression analyses and their effects were considered in its result. To evaluate the probability of the thrombosis-free survival of patients at different leukocyte counts (as introduced above), the Kaplan-Meier method was used, followed by the log-rank test (Mantel-Cox) 21 . Statistical significance was set at 5% and 10%.
Evaluation of the clinicohaematological role of the JAK2 V617F mutation
The Mann-Whitney test was performed in the case of the JAK2 V617F mutation- and/or with a prior thrombotic event 19, 20 . Statistical significance was set at 5% and 10%. 
Evaluation of the contributions of cardiovascular risk factors

Evaluation of the IPSET model on the thrombosis-free survival of the patients
The patients were subgrouped and the main clinical characteristics were compared on the basis of a 3-tiered prognostic model, IPSET 14 For the clinical utility of IPSET from the aspect of the thrombosis-free survival of the patients, the IPSET subgroups were compared by the Kaplan-Meier method followed by the log-rank test (Mantel-Cox) 21 . or with a median leukocyte count of 11.1 giga/L (p=0.478).
LABORATORY METHODS
Samples
RESULTS
THE CONTRIBUTION OF THE LEUKOCYTE COUNT ON SUBSEQUENT THROMBOTIC
COMPLICATIONS
THE PRESENCE OF THE JAK2 V617F, MPL AND CALR MUTATIONS AND THEIR
CLINICOHAEMATOLOGICAL ROLES
The JAK2 V617F mutation
From database 99-11, JAK2 V617F(+) cases were detected in 61 (60.39%) patients.
The comparison of the JAK2 V617F(+) and JAK2 V617F(-) patients by means of univariate analysis revealed no statistically significant association with the thrombotic complications (p=0.651) or with the separately analysed cardiovascular events (p=0.849), cerebrovascular events (p=0.558) or venous thrombotic events (p=0.849). An age > 60 years (p=0.060) and the median platelet count (p=0.042), the haemoglobin level (p=0.000), the red blood cell count (p=0.000) and the haematocrit (p=0.000) were significantly different in the JAK2 V617F(+) and JAK2 V617F(-) groups. The median white blood cell count was not significantly higher in the JAK2 V617F(+) group than in the JAK2 V617F(-) group (p=0.401).
At the haematological diagnosis of ET, a significantly higher number of hepatomegaly cases were observed in the JAK2 V617F(+) group than in the JAK2 V617F(-) group (p=0.045).
However, the numbers of splenomegaly cases (in the JAK2 V617F(+) group vs. in the JAK2 V617F(-) group (p=0.973)), and hepatosplenomegaly cases (in the JAK2 V617F(+) group vs.
in the JAK2 V617F(-) group (p=0.383)) did not show a significant difference 24 .
Multivariate binary logistic regression analysis on the subsequent thrombotic events after the diagnosis of ET revealed a significant partial effect of the prior thrombotic events (relative risk: 2.876, 95% CI 0.847-9.774; p=0.090), but a significant association was not observed between the JAK2 V617F mutation status (relative risk: 1.297, 95% CI 0.395-4.258; p=0.668), an age over 60 years (relative risk: 0.981, 95% CI 0.316-3.048; p=0.974) and the probability of subsequent thrombotic complications 24 .
To estimate the contribution of the presence of the JAK2 V617F mutation on the probability of thrombosis-free survival during the follow-up period, the JAK2 V617F(+), lowrisk patients, the JAK2 V617F (+) high-risk patients, the JAK2 V617F (-) low-risk patients and the JAK2 V617F(-) high-risk patients were compared via the Kaplan-Meier curves and the log-rank test (Mantel-Cox), which revealed only non-significant differences, p=0.548 24 .
The MPL and CALR mutations
The 
THE CONTRIBUTIONS OF THE CARDIOVASCULAR RISK FACTORS TO SUBSEQUENT
THROMBOTIC COMPLICATIONS
The univariate and multivariate statistical analyses based on database 99-11 revealed a significant overall association between the thrombotic complications and a high blood The administered therapy was incorporated in the analysis in order to consider its potential influence on the thrombotic events in the follow-up period. Although differences could be observed between the patients treated with antiplatelet (univariate: p=0.730) or cytoreductive therapy (univariate: p=0.319) in the two subgroups, depending on the presence or absence of major thrombotic events, but these differences were not significant.
the investigated cardiovascular risk factors, Kaplan-Meier curves and log-rank tests (Mantel-Cox) were utilized, which resulted in a significant difference between the thrombosis-free survival of the ET patients without cardiovascular risk factors (n=47) and those with at least one cardiovascular risk factor (n= 54) (p=0.011). A significant difference was also observed between the ET patients with at most one cardiovascular risk factor (n=77) and those with two or more cardiovascular risk factors (n=24) (p=0.002) 25 .
ANALYSES OF THE NEUROLOGICAL AND CARDIOLOGICAL CHARACTERISTICS OF THE CEREBROVASCULAR AND CARDIOVASCULAR COMPLICATIONS, AS THE MOST SEVERE THROMBOTIC COMPLICATIONS OF ET PATIENTS
Cerebrovascular complications
In 2012, database 99-11 revealed cerebrovascular complications (stroke/TIA/ vertebrobasilar insufficiency) in 4 males and 7 females with a median age of 67 years [range:
45-82 years]). The median platelet count at hematological diagnosis was 658 giga/L [range:
514-1157 giga/L], while at the time of the cerebrovascular events it was 450 giga/L [range:
320-885 giga/L]. All of the 11 analysed cases were JAK2 V617F(+). Mostly TIAs and/or minor strokes were noted. In most cases (8/11; 73%), the brain imaging modalities (skull CT and/or MRI) revealed periventricular and/or subcortical and/or basal ganglia lacunes or infarcts or confluent chronic white matter ischaemic lesions in all cerebral arterial regions.
There were hardly any infratentorial lesions. Atrophy with diverse degrees of severity was frequently seen (7/11; 64%). Mainly large infarcts were detected in the middle and posterior arterial regions in 4 patients, 3 of whom exhibited posterior watershed-type infarcts. In one, patient with a 665 giga/L platelet count, a haemorrhagic transformation of a large parietooccipital infarct was noted, without clinical deterioration. In 2 cases, the stroke complication itself drew attention to the presence of the underlying ET. Recurrent stroke or a vertebrobasilar insufficiency were seen despite the ongoing antiplatelet and cytoreductive therapy. No correlation was found between the platelet count and the stroke type or occurrence of stroke, although supratentorial lacunar infarcts and chronic white matter lesions predominated. It is important to note that most patients (7/11; 64%) displayed at least two or more serious conventional vascular risk factors. It could be suggested that these could have influenced both the clinical course and the morphological alterations seen on brain imaging 26 .
Detailed analyses on the cardiovascular complications based on database 99-14 in one case. Reccurrent MI events were not observed in the follow-up period. We found no correlation between the platelet counts and the MI type or the degree of stenosis.
THE IPSET MODEL AND THE THROMBOSIS-FREE SURVIVAL OF THE PATIENTS
Patients (based on database 99-14) were subgrouped and the main clinical characteristics were compared on the basis of the IPSET score 14 . From the data on the current cohort, the clinical characteristics of an intermediate-risk group of patients could be clearly differentiated from those of the low-and high-risk groups.
To compare the thrombosis-free survival of the patients categorized in the IPSET low-risk, IPSET intermediate-risk and IPSET high-risk groups, the Kaplan-Meier method was applied, followed by the log-rank test (Mantel-Cox), which resulted in significant differences between the different IPSET groups (p=0.002) 27 .
SUMMARY AND CONCLUSIONS
1. The reported incidence of thrombohaemorrhagic events in ET patients lies in the interval 11-25% [6] [7] [8] . Thrombotic events appear more commonly than haemorrhagic ones and among the thrombotic complications arterial thrombosis is more often observed than venous thrombosis 6 . In the current cohort in the period 1999-2014 retrospectively, the numbers of major thrombotic events that occurred previously were 30.32% and during the follow-up period 14.83% were evaluated. Arterial complications (80%) predominating over venous ones (20%).
2. The current goal of ET therapy is to prevent thrombohaemorrhagic complications 28 .
The haematological management strategy is based on risk-oriented recommendations, according to which the patients are stratified into low-and high-risk subgroups by the absence or presence of either an age > 60 years or a history of thrombosis 7, 19, 20 .
However, recent publications suggest that this two-categorical classical risk stratification may not be sufficiently sensitive. The impact of other additional risk factors on thrombosis, such as leukocytosis, JAK2 V617F mutation and the classic cardiovascular risk factors has recently been under active investigation 6, [11] [12] [13] [14] [15] [16] 29 .
a) Some literature studies suggest the contribution of the leukocyte count and leukocytosis at the diagnosis of ET to subsequent thrombotic events, but other reports did not verify this [30] [31] [32] [33] [34] [35] . Our findings on the current study population likewise did not confirm this suggestion. The leukocyte count cut-off value at the time of ET diagnosis relating to the current patient population (9.15 giga/L) was not associated with a higher risk of subsequent thrombotic complications either; likewise, the leukocytosis analysis did not indicate any potential association.
The leukocyte count measured at the time of the ET diagnosis, is probably not a sufficiently sensitive marker; its contribution is biologically plausible, but clinically uncertain.
b) The presence of the JAK2 V617F, MPL and CALR mutations in the current patient population was analysed. The revealed occurrence of these mutations and their impact on the clinicohaematological findings were in line with the relevant literature In ET, approximately 50-60% of the patients possess the JAK2 V617F mutation 6, 14 . In the current study population, 60-69.7% of the patients were found to harbour the mutation. It has been reported that JAK2 V617F(+) ET patients are older, have a higher rate of thrombohaemorrhagic complications, higher hemoglobin levels and a higher leukocyte counts than JAK2 V617F(-) patients [36] [37] [38] [39] [40] . In the current study, the JAK2 V617F(-) cases differed significantly from the JAK2 V617F(+) cases from the aspects of the platelet, haemoglobin, red blood cell and haematocrit counts and hepatomegaly. However, the presence of the mutation was not associated statistically significantly with an increased risk of thrombosis:
only non-significant tendencies were observed. In the IPSET risk stratification model, the predictive potential of the JAK2 V617F mutation on subsequent thrombosis was incorporated, and promising results were reported 14 . However it is important to note that the 2015 update on the diagnosis, risk stratification and management of ET does not provide a clear-cut standpoint as concerns the predictive role of the JAK2 V617F mutation in thrombotic complications 28 .
In JAK2 V617F(-) cases, other mutations have been investigated from the aspect of their influence in thrombotic complications, e.g. the MPL mutations (MPL W515L, MPL W515K, MPL W515R, MPL W515A, and MPL S505N) 9, 41-45 .
In ET, the most commonly detected (1-5%) MPL mutations are the W515L/K mutations 28, [46] [47] [48] . In current study population, genetic analysis of the JAK2 V617F(-) cohort revealed a 3.96% incidence of the MPL W515L mutation. It has been reported that MPL mutations may be associated with higher platelet counts, older age and a female predominance 43, 49 . In current study the patients who displayed the MPL W515L mutation were also older, were predominantly female and had higher platelet counts as compared with the JAK2 V617F(-), MPL W515L(-) patients. In the cases of JAK2 V617F(-) and MPL W515L(+) patients, we could observed lower numbers of thrombotic complications as compared with the JAK2 V617F(-) and MPL W515L(-) patients.
In JAK2 V617F-unmutated ET, the presence of CALR type-1 or type-2 somatic mutations has recently been identified with an estimated frequency of 15-32% 17, 50, 51 . Genetic analysis of our JAK2 V617F(-) cohort revealed CALR type-2 mutation positivity in 3 cases. It has been reported that a more indolent clinical course, with a younger age and a lower leukocyte count, but a higher platelet count and a decreased risk of thrombosis, may be observed among patients with CALR mutations 17, 50, 51 . In the current study the patients who harboured the CALR type-2 mutation were relatively young and had a lower median leukocyte count and a higher median platelet count at diagnosis, and in these cases a lower number of thrombotic complications were observed. IPSET subgroups, suggesting that this score system provides more information than the conventional thrombosis risk assessment. However, further prospective investigations are required to establish the potential advantages of the IPSET score system in everyday practice, and to determine whether cytoreductive treatment is necessary in the IPSET intermedier-risk subgroup. In the relevant literature up to
September 2014, only one external validation result is available on IPSET 52 . That analysis too demonstrated the significant differences in the cumulative thrombosis-free survival of ET patients classified by IPSET 52 .
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